Validation Data Gallery
Filter:
Tested Applications
| Positive FC detected in | Reh cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Flow Cytometry (FC) | FC : 0.25 ug per 10^6 cells in a 100 µl suspension |
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
Biotin-FcA98106 targets FLT3/CD135 in FC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
Recombinant Protein 相同性解析による交差性が予測される生物種 |
| Full Name | fms-related tyrosine kinase 3 |
| Calculated molecular weight | 993 aa, 113 kDa |
| GenBank accession number | BC036028 |
| Gene Symbol | FLT3 |
| Gene ID (NCBI) | 2322 |
| Conjugate | Biotin |
| Excitation/Emission maxima wavelengths | - |
| Form | |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P36888 |
| Storage Buffer | PBS with 0.09% sodium azide{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
FLT3 (also known as CD135 or FLK2) is a tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation, and survival of hematopoietic progenitor cells and of dendritic cells. FLT3 was originally identified by its expression in hematopoietic stem/progenitor cells (PMID: 7507245). It is important for the normal development of hematopoietic stem/progenitor cells. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for Biotin FLT3/CD135 antibody Biotin-FcA98106 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |